ALICE: a randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer

被引：0
|
作者：
J. A. Kyte
A. Røssevold
R. S. Falk
B. Naume
机构：
[1] Oslo University Hospital,Department of Clinical Cancer Research
[2] Oslo University Hospital,Department of Cancer Immunology
[3] Oslo University Hospital,Department of Oncology
[4] Oslo University Hospital,Oslo Centre for Biostatistics and Epidemiology
[5] University of Oslo,Institute of Clinical Medicine
来源：
Journal of Translational Medicine | / 18卷
关键词：
Breast cancer; Triple negative; Immunotherapy; Checkpoint inhibitor; Immunogenic cell death; PD-1; PD-L1; Anthracycline; Cyclophosphamide;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] ICON: a randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer
    Kyte, J. A.
    Andresen, N. K.
    Russnes, H. G.
    Fretland, S. O.
    Falk, R. S.
    Lingjaerde, O. C.
    Naume, B.
    JOURNAL OF TRANSLATIONAL MEDICINE, 2020, 18 (01)
  • [32] A phase II trial of atezolizumab (anti-PD-L1) with carboplatin in patients with metastatic triple-negative breast cancer (mTNBC).
    Lander, Eric Michael
    Lehmann, Brian David
    Shah, Payal D.
    Dees, Elizabeth Claire
    Ballinger, Tarah Jean
    Pohlmann, Paula Raffin
    Santa-Maria, Cesar Augusto
    Shyr, Yu
    Mayer, Ingrid A.
    Park, Ben Ho
    Pietenpol, Jennifer A.
    Abramson, Vandana G.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [33] A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida)
    Goldstein, Lori J.
    Mansutti, Mauro
    Levy, Christelle
    Chang, Jenny C.
    Henry, Stephanie
    Fernandez-Perez, Isaura
    Prausova, Jana
    Staroslawska, Elzbieta
    Viale, Giuseppe
    Butler, Beth
    McCanna, Susan
    Ruffini, Pier Adelchi
    Wicha, Max S.
    Schott, Anne F.
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 190 (02) : 265 - 275
  • [34] A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida)
    Lori J. Goldstein
    Mauro Mansutti
    Christelle Levy
    Jenny C. Chang
    Stephanie Henry
    Isaura Fernandez-Perez
    Jana Prausovà
    Elzbieta Staroslawska
    Giuseppe Viale
    Beth Butler
    Susan McCanna
    Pier Adelchi Ruffini
    Max S. Wicha
    Anne F. Schott
    Breast Cancer Research and Treatment, 2021, 190 : 265 - 275
  • [35] A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis
    Brufsky, A.
    Kim, S. B.
    Zvirbule, Z.
    Eniu, A.
    Mebis, J.
    Sohn, J. H.
    Wongchenko, M.
    Chohan, S.
    Amin, R.
    Yan, Y.
    McNally, V
    Miles, D.
    Loi, S.
    ANNALS OF ONCOLOGY, 2021, 32 (05) : 652 - 660
  • [36] A Phase II randomized trial of pembrolizumab with carboplatin and gemcitabine for treatment of patients with metastatic triple-negative breast cancer (mTNBC)
    Obeid, E.
    Miller, K. D.
    Sparano, J. A.
    Blackwell, K.
    Goldstein, L. J.
    CANCER RESEARCH, 2017, 77
  • [37] A phase Ib/II study of leronlimab combined with carboplatin in patients with CCR5+metastatic triple-negative breast cancer (mTNBC)
    Cristofanilli, Massimo
    Chittoria, Namita
    Ehsani, Sima
    Rui, Hallgeir
    Dolezal, Milana
    Stork-Sloots, Lisette
    de Snoo, Femke
    Recknor, Christopher
    Abramson, Vandana
    CANCER RESEARCH, 2022, 82 (04)
  • [38] Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer The TBCRC 043 Phase 2 Randomized Clinical Trial
    Lehmann, Brian D.
    Abramson, Vandana G.
    Dees, E. Claire
    Shah, Payal D.
    Ballinger, Tarah J.
    Isaacs, Claudine
    Santa-Maria, Cesar A.
    An, Hanbing
    Gonzalez-Ericsson, Paula I.
    Sanders, Melinda E.
    Newsom, Kimberly C.
    Abramson, Richard G.
    Sheng, Quanhu
    Hsu, Chih-Yuan
    Shyr, Yu
    Wolff, Antonio C.
    Pietenpol, Jennifer A.
    JAMA ONCOLOGY, 2024, 10 (02) : 193 - 201
  • [39] A phase II study of nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer (mTNBC).
    Barroso-Sousa, Romualdo
    Guo, Hao
    Barry, William Thomas
    Winship, Grace
    Overmoyer, Beth
    Duda, Dan G.
    Tolaney, Sara M.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [40] Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study
    Barroso-Sousa, Romualdo
    Keenan, Tanya E.
    Li, Tianyu
    Tayob, Nabihah
    Trippa, Lorenzo
    Pastorello, Ricardo G.
    Richardson, Edward T., III
    Dillon, Deborah
    Amoozgar, Zohreh
    Overmoyer, Beth
    Schnitt, Stuart J.
    Winer, Eric P.
    Mittendorf, Elizabeth A.
    Van Allen, Eliezer
    Duda, Dan G.
    Tolaney, Sara M.
    NPJ BREAST CANCER, 2021, 7 (01)
12345